Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
100 Results for "
DYRK1
" in MedChemExpress (MCE) Product Catalog:
Products (100)
100 Results for "DYRK1" in MCE Product Catalog:
Cat. No.: HY-159496
CAS No.: 2891824-14-7
Target:
Research Areas:
Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar [1].
Cat. No.: HY-157995
Target:
Research Areas:
Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC50 value of DYRK1A is 28 nM. For CLK2, Kd is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases [1].
Cat. No.: HY-101029A
CAS No.: 2083624-07-9
Target:
Research Areas:
MBM-55S is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC50=5.4 nM) and DYRK1a (IC50=6.5 nM). MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55S shows antitumor activities, and no obvious toxicity to mice [1].
Cat. No.: HY-162597
Target:
Research Areas:
Dyrk1A-IN-9 (Compound L9) is a moderately active DYRK1A inhibitor (IC50: 1.67 μM). L9 shows neuroprotective activity by regulating the expression of Aβ and phosphorylation of Tau protein. Dyrk1A-IN-9 can be used for research of Alzheimer's disease [1].
Cat. No.: HY-144695
CAS No.: 2789711-47-1
Target:
Research Areas:
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual Dyrk1A and α-synuclein aggregation inhibitor with IC50 values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect [1].
Cat. No.: HY-144696
CAS No.: 2789711-66-4
Target:
Research Areas:
Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual Dyrk1A and α-synuclein aggregation inhibitor with an IC50 of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect [1].
Cat. No.: HY-150537
CAS No.: 2412364-73-7
Research Areas:
AChE/GSK-3β-IN-1 (compound GT15) is a potent, dual AChE/GSK-3β inhibitor with IC50 values of 1.2, 149.8 and 22.4 nM for hAChE , hBChE and hGSK-3β, respectively. AChE/GSK-3β-IN-1 penetrates the blood-brain barrier (BBB). AChE/GSK-3β-IN-1 has high kinase selectivity profiles for the CMGC kinase family. AChE/GSK-3β-IN-1 occupies the ATP binding site of DYRK1A. AChE/GSK-3β-IN-1 inhibits ROS expression and reduces oxidative stress. AChE/GSK-3β-IN-1 can be used for Alzheimer’s disease research [1].
Cat. No.: HY-RS04095
Target:
Research Areas:
Dyrk1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dyrk1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS04096
Target:
Research Areas:
Dyrk1a Rat Pre-designed siRNA Set A contains three designed siRNAs for Dyrk1a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS04097
Target:
Research Areas:
DYRK1B Human Pre-designed siRNA Set A contains three designed siRNAs for DYRK1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS17311
Target:
Research Areas:
Dyrk1b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dyrk1b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23766
Target:
Research Areas:
Dyrk1b Rat Pre-designed siRNA Set A contains three designed siRNAs for Dyrk1b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-W067583
CAS No.: 6253-19-6
Target:
Research Areas:
Norharmine is a Harmine analogue and an alkaloid. Norharmine is the inhibitors of MAO-A and DYRK1A. Norharmine has weak inhibitory activity against MAO-A and certain inhibitory activity against DYRK1A [1].
Cat. No.: HY-P701667
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: DYRK1A; HP86; Prev. DYRK; Serine/Threonine-Specific Protein Kinase; Prev. MNBH; Mnb Protein Kinase Homolog Hp86; Prev. DYRK1; Serine/Threonine Kinase MNB; Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A; MNB/DYRK Protein Kinase; Protein Kina
Species:
Human
Source:
E. coli
Cat. No.: HY-P701668
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: DYRK1A; HP86; Prev. DYRK; Serine/Threonine-Specific Protein Kinase; Prev. MNBH; Mnb Protein Kinase Homolog Hp86; Prev. DYRK1; Serine/Threonine Kinase MNB; Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A; MNB/DYRK Protein Kinase; Protein Kina
Species:
Human
Source:
E. coli
Cat. No.: HY-P3992
Target:
Research Areas:
Target:
Research Areas:
AnnH31 is a Dyrk1A inhibitor (IC50: 81 nM). AnnH31 also inhibits MAO-A with an IC50 of 3.2 μM. AnnH31 inhibits cell viability of HeLa, PC12 and SH-SY5Y cells [1].
Cat. No.: HY-179599
CAS No.: 1448757-02-5
Research Areas:
Dyrk1A-IN-15 is a selective, brain-penetrant and ATP-competitive Dyrk1A inhibitor with a IC50 of 19 nM. Dyrk1A-IN-15 displays high selectivity across a broad kinase panel (specific for DYRK kinases) with nanomolar potency. Dyrk1A-IN-15 impairs neurosphere self-renewal, cell invasion, and EGFR stability in vitro. Dyrk1A-IN-15 inhibits tumor growth and prolongs survival in vivo. Dyrk1A-IN-15 has potential for glioblastoma (GBM) research [1].
Cat. No.: HY-179600
CAS No.: 2805339-74-4
Research Areas:
Dyrk1A-IN-16 is a selective, brain-penetrant and ATP-competitive Dyrk1A inhibitor with a IC50 of 53 nM. Dyrk1A-IN-16 displays high selectivity across a broad kinase panel (specific for DYRK kinases) with nanomolar potency. Dyrk1A-IN-16 impairs neurosphere self-renewal, cell invasion, and EGFR stability in vitro. Dyrk1A-IN-16 inhibits tumor growth and prolongs survival in vivo. Dyrk1A-IN-16 has potential for glioblastoma (GBM) research [1].
Cat. No.: HY-163514
Target:
Research Areas:
hAChE-IN-8 (Compound S-12) is a orally effective and selective inhibitor of hAChE (IC50=0.486 μM). hAChE-IN-8 also inhibits BACE-1 (IC50=0.542 μM), and does not inhibit Dyrk1A (IC50>10 μM). hAChE-IN-8 can reduce Aβ aggregation, has good blood-brain barrier penetration. hAChE-IN-8 is mainly used in Alzheimer's disease research [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
